This is a study to test the safety of ALKS 5461 in healthy adults.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
104
Alkermes Investigational Site
Overland Park, Kansas, United States
Relative bioavailability of ALKS 5461 treatment groups
The parameters for determining the bioavailability include Cmax, AUC last, and AUC(0-infinity).
Time frame: 21 days
Safety and tolerability: Incidence of adverse events
Time frame: 21 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.